ES2738526T3 - Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos - Google Patents
Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos Download PDFInfo
- Publication number
- ES2738526T3 ES2738526T3 ES12781534T ES12781534T ES2738526T3 ES 2738526 T3 ES2738526 T3 ES 2738526T3 ES 12781534 T ES12781534 T ES 12781534T ES 12781534 T ES12781534 T ES 12781534T ES 2738526 T3 ES2738526 T3 ES 2738526T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- substituted
- unsubstituted
- solution
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@](CC1)([C@](CC2)[C@@](CC3)[C@]1[C@@](CC1)[C@]3C[C@]1(C#CCl)O)[C@]2C(CS*)=O Chemical compound C[C@](CC1)([C@](CC2)[C@@](CC3)[C@]1[C@@](CC1)[C@]3C[C@]1(C#CCl)O)[C@]2C(CS*)=O 0.000 description 5
- BJGRFMVIXJYDHI-COVJHCGESA-N CC(CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)[C@@H]3C[C@@]1(COC)O)C2C(CO)=O Chemical compound CC(CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)[C@@H]3C[C@@]1(COC)O)C2C(CO)=O BJGRFMVIXJYDHI-COVJHCGESA-N 0.000 description 1
- UMHMVRANVZYDNS-ZJGJLQLSSA-N CC(CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(CBr)=O Chemical compound CC(CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(CBr)=O UMHMVRANVZYDNS-ZJGJLQLSSA-N 0.000 description 1
- LETMEIKVOWOVIE-GKEUNLPTSA-N CCC[C@@](C[C@H](CC1)C[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(C[n]1cncc1)=O)(COC)O Chemical compound CCC[C@@](C[C@H](CC1)C[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(C[n]1cncc1)=O)(COC)O LETMEIKVOWOVIE-GKEUNLPTSA-N 0.000 description 1
- SLHJGNMPRYDGCK-DDHVEKBHSA-N CCC[C@](C)(C[C@H](CC1)C[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(C[n]1nccn1)=O)O Chemical compound CCC[C@](C)(C[C@H](CC1)C[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(C[n]1nccn1)=O)O SLHJGNMPRYDGCK-DDHVEKBHSA-N 0.000 description 1
- NOPMRWKAPOQHLJ-ZEFRRGKSSA-N C[C@@H](CC1)CC(CC2)[C@H]1C(CC1)C2C(CC2)[C@@]1(C)[C@H]2C(C)=O Chemical compound C[C@@H](CC1)CC(CC2)[C@H]1C(CC1)C2C(CC2)[C@@]1(C)[C@H]2C(C)=O NOPMRWKAPOQHLJ-ZEFRRGKSSA-N 0.000 description 1
- WXWCDZPOMIUNPM-CJRUCWEJSA-N C[C@@H](CC1)[C@@H](CC[C@@H](C2)CC=C[C@]2(O)OC)[C@H](CC2)[C@]1(C)[C@H]2C(C)=O Chemical compound C[C@@H](CC1)[C@@H](CC[C@@H](C2)CC=C[C@]2(O)OC)[C@H](CC2)[C@]1(C)[C@H]2C(C)=O WXWCDZPOMIUNPM-CJRUCWEJSA-N 0.000 description 1
- WHTAGOHJUYRPKE-OETXNUODSA-N C[C@H](C1)[C@H](C[C@@](C)(CC2)O)[C@H]2[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(C)=O Chemical compound C[C@H](C1)[C@H](C[C@@](C)(CC2)O)[C@H]2[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(C)=O WHTAGOHJUYRPKE-OETXNUODSA-N 0.000 description 1
- NDYZXPKPZRWYJV-NQNAPEONSA-N C[C@H](C1)[C@H](C[C@@](C)(CC2)O)[C@H]2[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(CBr)=O Chemical compound C[C@H](C1)[C@H](C[C@@](C)(CC2)O)[C@H]2[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(CBr)=O NDYZXPKPZRWYJV-NQNAPEONSA-N 0.000 description 1
- YUYCUNPFXFPMMW-NQNAPEONSA-N C[C@H](C1)[C@H](C[C@@](C)(CC2)O)[C@H]2[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(CO)=O Chemical compound C[C@H](C1)[C@H](C[C@@](C)(CC2)O)[C@H]2[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(CO)=O YUYCUNPFXFPMMW-NQNAPEONSA-N 0.000 description 1
- NSGSGROCHJEOIK-BJZHTQEZSA-N C[C@H](CC1)[C@@H](CC[C@@](COC)(C2)O)[C@H]2CCC[C@H](CC2)C1(C)[C@H]2C(C)=O Chemical compound C[C@H](CC1)[C@@H](CC[C@@](COC)(C2)O)[C@H]2CCC[C@H](CC2)C1(C)[C@H]2C(C)=O NSGSGROCHJEOIK-BJZHTQEZSA-N 0.000 description 1
- UORBDGZWPNKERU-WKXDXTRLSA-N C[C@](CC1)([C@@H](C2)[C@H](CC3)[C@H]1C(CC[C@@](COC)(C1)O)[C@@]31N=C)C2Br Chemical compound C[C@](CC1)([C@@H](C2)[C@H](CC3)[C@H]1C(CC[C@@](COC)(C1)O)[C@@]31N=C)C2Br UORBDGZWPNKERU-WKXDXTRLSA-N 0.000 description 1
- SPZWQCAIQBFUOQ-SGJHKPSISA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@@]1(O)OC)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@@]1(O)OC)[C@H]2C(CO)=O SPZWQCAIQBFUOQ-SGJHKPSISA-N 0.000 description 1
- UVGUZLGBXVHUPV-HKHBUPFLSA-N C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@@H](C1)OC(C)=O)[C@H]1C3=C)C21OCCO1 Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@@H](C1)OC(C)=O)[C@H]1C3=C)C21OCCO1 UVGUZLGBXVHUPV-HKHBUPFLSA-N 0.000 description 1
- ZGISVRXPAWFDON-LXGGTWONSA-N C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@@H](C1)OC(C)=O)[C@H]1C3=O)C21OCCO1 Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@@H](C1)OC(C)=O)[C@H]1C3=O)C21OCCO1 ZGISVRXPAWFDON-LXGGTWONSA-N 0.000 description 1
- MICWPNVHGQVWKU-KQBFAJRKSA-N C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@@H](C1)OC(C)=O)[C@H]1[C@H]3O)C21OCCO1 Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@@H](C1)OC(C)=O)[C@H]1[C@H]3O)C21OCCO1 MICWPNVHGQVWKU-KQBFAJRKSA-N 0.000 description 1
- ZRWGKZRIULCWMU-DZICADCFSA-N C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1[C@@H]3F)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1[C@@H]3F)[C@H]2C(C)=O ZRWGKZRIULCWMU-DZICADCFSA-N 0.000 description 1
- SZJSEMWMLTYQGH-NYBZHNPDSA-N C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1[C@@H]3F)[C@H]2C(CBr)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1[C@@H]3F)[C@H]2C(CBr)=O SZJSEMWMLTYQGH-NYBZHNPDSA-N 0.000 description 1
- RHDNXUPWQGVYIA-NYBZHNPDSA-N C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1[C@@H]3F)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1[C@@H]3F)[C@H]2C(CO)=O RHDNXUPWQGVYIA-NYBZHNPDSA-N 0.000 description 1
- LDIWEDPNAVDNSJ-YSLAPMGRSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(C[n]1cncc1)=O LDIWEDPNAVDNSJ-YSLAPMGRSA-N 0.000 description 1
- HQJUHJWMHWEYBR-URDRGLOHSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(C[n]1nccn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(C[n]1nccn1)=O HQJUHJWMHWEYBR-URDRGLOHSA-N 0.000 description 1
- ZIUUNICRKIQAKD-QRQKOEFOSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CCl)O)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CCl)O)[C@H]2C(C[n]1cncc1)=O ZIUUNICRKIQAKD-QRQKOEFOSA-N 0.000 description 1
- TXCABTBXHSNKOJ-WWIDNNBLSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CCl)O)[C@H]2C(C[n]1nccn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CCl)O)[C@H]2C(C[n]1nccn1)=O TXCABTBXHSNKOJ-WWIDNNBLSA-N 0.000 description 1
- JKRYNZRUWKBASC-RCSOYHDBSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C(F)F)O)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C(F)F)O)[C@H]2C(C[n]1cncc1)=O JKRYNZRUWKBASC-RCSOYHDBSA-N 0.000 description 1
- XNUZAYHRYOOSFX-YRTSKKSESA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(CF)O)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(CF)O)[C@H]2C(C[n]1cncc1)=O XNUZAYHRYOOSFX-YRTSKKSESA-N 0.000 description 1
- GLMMXZCVUUYNKR-CRGJMJCGSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(CF)O)[C@H]2C(C[n]1nccn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(CF)O)[C@H]2C(C[n]1nccn1)=O GLMMXZCVUUYNKR-CRGJMJCGSA-N 0.000 description 1
- JIWJWZQRCFJBIU-QJCJHIBTSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C)=O JIWJWZQRCFJBIU-QJCJHIBTSA-N 0.000 description 1
- XNVUVEDLYYEQOS-YRTSKKSESA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C[n]1nccn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C[n]1nccn1)=O XNVUVEDLYYEQOS-YRTSKKSESA-N 0.000 description 1
- NTFXROHUKRNXEE-CLYQZSFASA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(C)=O NTFXROHUKRNXEE-CLYQZSFASA-N 0.000 description 1
- FQEQBPAQVZLYME-DCPTXXHLSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(CO)=O FQEQBPAQVZLYME-DCPTXXHLSA-N 0.000 description 1
- QMZLDCPSAVTNRY-DWZOGCISSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CCl)O)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CCl)O)[C@H]2C(CO)=O QMZLDCPSAVTNRY-DWZOGCISSA-N 0.000 description 1
- FRPFNZSDZDILPT-VCSUUWALSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C(F)F)O)[C@H]2C(CBr)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C(F)F)O)[C@H]2C(CBr)=O FRPFNZSDZDILPT-VCSUUWALSA-N 0.000 description 1
- IDOZPADGFLFDRO-VCSUUWALSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C(F)F)O)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C(F)F)O)[C@H]2C(CO)=O IDOZPADGFLFDRO-VCSUUWALSA-N 0.000 description 1
- VOZOMZWSLGQRKP-SMPVXYKMSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C)=O VOZOMZWSLGQRKP-SMPVXYKMSA-N 0.000 description 1
- JOEGIEGOLJKYIO-MEFKEFOCSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC[C@@]14O)[C@@H]3C1C4(F)F)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC[C@@]14O)[C@@H]3C1C4(F)F)[C@H]2C(C)=O JOEGIEGOLJKYIO-MEFKEFOCSA-N 0.000 description 1
- KELRVUIFMYCLHB-MTLKIPAASA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@@H](C1)O)C1=CC3)C2=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@@H](C1)O)C1=CC3)C2=O KELRVUIFMYCLHB-MTLKIPAASA-N 0.000 description 1
- NXCBOIYBNCKRJS-WQUGUCIPSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@@](C1)(C(F)F)O)C1=CC3)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@@](C1)(C(F)F)O)C1=CC3)[C@H]2C(C)=O NXCBOIYBNCKRJS-WQUGUCIPSA-N 0.000 description 1
- CBFHLGAYEQYENW-ZQXMCZQSSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1C(C)(C)C3)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1C(C)(C)C3)[C@H]2C(C)=O CBFHLGAYEQYENW-ZQXMCZQSSA-N 0.000 description 1
- JLBOUNFDCKLETJ-MTJVMKCNSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1C(C)(C)C3)[C@H]2C(CBr)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1C(C)(C)C3)[C@H]2C(CBr)=O JLBOUNFDCKLETJ-MTJVMKCNSA-N 0.000 description 1
- ZLKOAMQLQHOQPX-MTJVMKCNSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1C(C)(C)C3)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1C(C)(C)C3)[C@H]2C(CO)=O ZLKOAMQLQHOQPX-MTJVMKCNSA-N 0.000 description 1
- ORHCHJPLWPHIJR-VNEVJAEPSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](COC)(C1)O)C1=CC3)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](COC)(C1)O)C1=CC3)[C@H]2C(C)=O ORHCHJPLWPHIJR-VNEVJAEPSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547291P | 2011-10-14 | 2011-10-14 | |
| US201261698204P | 2012-09-07 | 2012-09-07 | |
| PCT/US2012/060136 WO2013056181A1 (en) | 2011-10-14 | 2012-10-12 | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2738526T3 true ES2738526T3 (es) | 2020-01-23 |
Family
ID=47143295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12781534T Active ES2738526T3 (es) | 2011-10-14 | 2012-10-12 | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20150291654A1 (enExample) |
| EP (2) | EP3572417B1 (enExample) |
| JP (5) | JP2014528485A (enExample) |
| CN (4) | CN108976272B (enExample) |
| AU (6) | AU2012323888A1 (enExample) |
| CA (2) | CA2852057C (enExample) |
| ES (1) | ES2738526T3 (enExample) |
| PT (1) | PT2766380T (enExample) |
| WO (1) | WO2013056181A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101583620B (zh) | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
| US20150158903A1 (en) | 2011-09-08 | 2015-06-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| WO2013112605A2 (en) | 2012-01-23 | 2013-08-01 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
| IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| EP4335505A3 (en) | 2012-11-30 | 2024-06-05 | The Regents of The University of California | Anticonvulsant activity of steroids |
| LT2968369T (lt) | 2013-03-13 | 2018-12-27 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai ir jų panaudojimo būdai |
| HRP20200995T1 (hr) * | 2013-04-17 | 2020-11-27 | Sage Therapeutics, Inc. | 19-nor neuroaktivni steroidi za metode liječenja |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| HRP20190232T1 (hr) * | 2013-04-17 | 2019-03-22 | Sage Therapeutics, Inc. | 19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu upotrebu |
| WO2014169831A1 (en) * | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| SMT202100229T1 (it) | 2013-07-19 | 2021-05-07 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
| SMT202100048T1 (it) * | 2013-08-23 | 2021-03-15 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
| HUE050028T2 (hu) * | 2014-05-29 | 2021-12-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásuk |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| TW201625660A (zh) * | 2014-09-17 | 2016-07-16 | 普瑞弗克斯公司 | Ｃ－２０類固醇化合物、其組成物及用於治療包含震盪之創傷性腦損傷（ｔｂｉ）的用途 |
| JP6742308B2 (ja) * | 2014-10-16 | 2020-08-19 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
| AU2015331749A1 (en) * | 2014-10-16 | 2017-05-04 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| ES2793237T3 (es) | 2014-11-27 | 2020-11-13 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| SI3250210T1 (sl) | 2015-01-26 | 2021-07-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016164763A1 (en) * | 2015-04-10 | 2016-10-13 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| AR105044A1 (es) | 2015-06-18 | 2017-08-30 | Sage Therapeutics Inc | Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente |
| MA42409A (fr) | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| RS62220B1 (sr) | 2015-07-06 | 2021-09-30 | Sage Therapeutics Inc | Oksisteroli i postupci njihovog korišćenja |
| MX376833B (es) | 2015-07-06 | 2025-03-07 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| EP3362042A1 (en) | 2015-10-16 | 2018-08-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| SG11201807785VA (en) | 2016-03-08 | 2018-10-30 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| CN114272249A (zh) | 2016-04-01 | 2022-04-05 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| AU2017292870B2 (en) | 2016-07-07 | 2021-10-07 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN109689673B (zh) * | 2016-07-11 | 2023-03-14 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| WO2018031748A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| CN115974954A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| EP3519422B1 (en) | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | C7 substituted oxysterols and these compounds for use as nmda modulators |
| KR20250054838A (ko) | 2016-10-18 | 2025-04-23 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| ES2952106T3 (es) | 2016-10-18 | 2023-10-27 | Sage Therapeutics Inc | Oxisteroles y procedimientos de utilización de los mismos |
| WO2019075362A1 (en) * | 2017-10-12 | 2019-04-18 | Sage Therapeutics, Inc. | METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| MA51315A (fr) | 2017-12-22 | 2020-10-28 | Sage Therapeutics Inc | Compositions et méthodes permettant de traiter des troubles du snc |
| CA3088919A1 (en) * | 2018-02-11 | 2019-08-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
| CN114656514B (zh) | 2018-02-11 | 2024-05-14 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| BR112021010996A2 (pt) | 2018-12-05 | 2021-08-31 | Sage Therapeutics, Inc. | Esteroides neuroativos e seus métodos de uso |
| WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
| WO2020132504A1 (en) | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
| CA3145923A1 (en) | 2019-08-05 | 2021-02-11 | David Czekai | Ganaxolone for use in treatment of status epilepticus |
| WO2021023213A1 (zh) * | 2019-08-07 | 2021-02-11 | 上海翰森生物医药科技有限公司 | 一种甾族类衍生物调节剂的盐及其晶型 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| US20210188897A1 (en) * | 2019-12-05 | 2021-06-24 | Sparx Therapeutics, Inc. | Neuroactive steroids and compositions and methods thereof |
| WO2021113834A1 (en) | 2019-12-06 | 2021-06-10 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
| IL295902A (en) * | 2020-02-27 | 2022-10-01 | Brii Biosciences Inc | Drug inhibitors of neuroactive steroids |
| US20230346801A1 (en) | 2020-03-25 | 2023-11-02 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| CA3226489A1 (en) | 2021-07-28 | 2023-02-02 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
| KR20250022070A (ko) * | 2022-06-09 | 2025-02-14 | 산동 루예 파마슈티칼 컴파니 리미티드 | 19-노르 c3,3-이치환된 c21-아자헤테로고리 치환 스테로이드 및 이의 사용 방법 |
| WO2024059608A1 (en) | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
| WO2024189061A1 (en) | 2023-03-14 | 2024-09-19 | Curia Spain, S.A.U. | Process and intermediates for the preparation of 3alpha-hydroxy-3beta-alkyl steroids |
| WO2025119319A1 (zh) * | 2023-12-08 | 2025-06-12 | 山东绿叶制药有限公司 | 一种gabaa受体调节剂的晶型及其制备方法和应用 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1994E (fr) | 1902-11-20 | 1903-11-24 | Jules Bernard | Dispositif de suspension élastique amortisseur de chocs pour chassis, caisses de véhicules, sièges et sommiers élastiques |
| US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| GB1380246A (en) | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| GB1436324A (en) | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| US4192871A (en) * | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| JPH03500049A (ja) * | 1987-08-25 | 1991-01-10 | ジー、ケルビン・ダブリュー | ストレス、不安および発作活性の緩和のための組成物および方法 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP0603312A4 (en) | 1991-09-13 | 1995-06-07 | Cocensys Inc | NEW GABA A RECEPTOR WITH STEROID BINDING POINTS. |
| DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| NZ282939A (en) | 1994-02-14 | 1998-08-26 | Cocensys Inc | Androstanes and pregnanes for allosteric modulation of gaba receptors |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| AU3125695A (en) | 1994-07-21 | 1996-02-22 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
| WO1996016076A1 (en) * | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| KR19990022323A (ko) * | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
| CN1187367C (zh) | 1999-04-29 | 2005-02-02 | 欧洲凯尔特股份有限公司 | 具有麻醉剂活性的3α－羟基－3β－甲氧基甲基－21－杂环取代的类固醇 |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| EP1172371B1 (en) | 2000-02-18 | 2005-06-08 | Taiho Pharmaceutical Company Limited | Process for the preparation of steroid derivatives |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| WO2002036605A2 (en) | 2000-11-03 | 2002-05-10 | Washington University | Estrone-derivatives having cytoprotective activity |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| EA011123B1 (ru) | 2003-03-24 | 2008-12-30 | Стерикс Лимитед | Производные эстрогена в качестве ингибиторов стероидной сульфатазы |
| US7781421B2 (en) | 2003-05-29 | 2010-08-24 | Washington University | Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods |
| JP2007512344A (ja) | 2003-11-24 | 2007-05-17 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体調節剤 |
| US20090118248A1 (en) | 2004-04-23 | 2009-05-07 | Euro-Celtique S.A. | 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| WO2006110172A2 (en) | 2004-09-29 | 2006-10-19 | Hollis-Eden Pharmaceuticals.Inc. | Steroid analogs and characterization and treatment methods |
| PT2168585E (pt) | 2005-06-09 | 2012-03-05 | Euro Celtique Sa | Composições farmacêuticas de um esteróide neuroactivo e as suas utilizações |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| AU2008265898B2 (en) | 2007-06-15 | 2013-11-28 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| CZ2008434A3 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| EP2598513A1 (en) | 2010-07-30 | 2013-06-05 | Medexis S.A. | Compounds and methods for treating neoplasia |
| EP2667876A2 (en) | 2010-12-15 | 2013-12-04 | Harbor BioSciences, Inc. | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
| CZ303443B6 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| US9457033B2 (en) | 2011-02-15 | 2016-10-04 | Socpra Sciences Et Genie, S.E.C. | Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| EP2695948B1 (en) | 2011-03-23 | 2016-12-28 | Etsuro Ito | Method and kit for super-high-sensitivity measurement of protein and nucleic acid, and novel enzyme substrate |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| US20150158903A1 (en) | 2011-09-08 | 2015-06-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| ES3056529T3 (en) | 2012-11-09 | 2026-02-23 | Drawbridge Pharmaceuticals Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| BR112015014397B1 (pt) | 2012-12-18 | 2021-02-02 | Washington University | composto, composição farmacêutica e uso de um composto |
| US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| HRP20200995T1 (hr) | 2013-04-17 | 2020-11-27 | Sage Therapeutics, Inc. | 19-nor neuroaktivni steroidi za metode liječenja |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| HRP20190232T1 (hr) | 2013-04-17 | 2019-03-22 | Sage Therapeutics, Inc. | 19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu upotrebu |
| SMT202100229T1 (it) | 2013-07-19 | 2021-05-07 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
| SMT202100048T1 (it) | 2013-08-23 | 2021-03-15 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
| HUE050028T2 (hu) | 2014-05-29 | 2021-12-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásuk |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| AU2015331749A1 (en) | 2014-10-16 | 2017-05-04 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| JP6742308B2 (ja) | 2014-10-16 | 2020-08-19 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
| ES2793237T3 (es) | 2014-11-27 | 2020-11-13 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| SI3250210T1 (sl) | 2015-01-26 | 2021-07-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| CN108350021A (zh) | 2015-09-08 | 2018-07-31 | 视点医疗公司 | 用于治疗眼科疾病的化合物和制剂 |
| EP3362042A1 (en) | 2015-10-16 | 2018-08-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| US20200306262A1 (en) | 2015-11-20 | 2020-10-01 | Sage Therapeutics, Inc. | Compounds and methods of their use |
| SG11201807785VA (en) | 2016-03-08 | 2018-10-30 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| CN109689673B (zh) | 2016-07-11 | 2023-03-14 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
| CN115974954A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| KR102680786B1 (ko) | 2017-08-31 | 2024-07-02 | 다케다 야쿠힌 고교 가부시키가이샤 | Cns 병태의 치료 |
-
2012
- 2012-10-12 ES ES12781534T patent/ES2738526T3/es active Active
- 2012-10-12 AU AU2012323888A patent/AU2012323888A1/en not_active Abandoned
- 2012-10-12 CA CA2852057A patent/CA2852057C/en active Active
- 2012-10-12 CA CA3152410A patent/CA3152410A1/en active Pending
- 2012-10-12 EP EP19169283.9A patent/EP3572417B1/en active Active
- 2012-10-12 CN CN201810869360.3A patent/CN108976272B/zh active Active
- 2012-10-12 US US14/351,449 patent/US20150291654A1/en not_active Abandoned
- 2012-10-12 CN CN202411226456.XA patent/CN119192266A/zh active Pending
- 2012-10-12 CN CN202110494113.1A patent/CN113234114A/zh active Pending
- 2012-10-12 CN CN201280060883.4A patent/CN104136452A/zh active Pending
- 2012-10-12 JP JP2014535962A patent/JP2014528485A/ja not_active Withdrawn
- 2012-10-12 EP EP12781534.8A patent/EP2766380B1/en active Active
- 2012-10-12 WO PCT/US2012/060136 patent/WO2013056181A1/en not_active Ceased
- 2012-10-12 PT PT12781534T patent/PT2766380T/pt unknown
-
2017
- 2017-07-26 AU AU2017208284A patent/AU2017208284B2/en active Active
- 2017-08-21 US US15/681,983 patent/US10435431B2/en active Active
- 2017-12-07 JP JP2017235371A patent/JP6745783B2/ja active Active
-
2019
- 2019-04-30 AU AU2019203046A patent/AU2019203046B2/en active Active
- 2019-08-22 US US16/548,248 patent/US20200223884A1/en not_active Abandoned
-
2020
- 2020-08-04 JP JP2020132282A patent/JP7096864B2/ja active Active
- 2020-10-22 US US17/077,025 patent/US20210040141A1/en not_active Abandoned
-
2021
- 2021-07-08 AU AU2021204782A patent/AU2021204782B2/en active Active
-
2022
- 2022-06-24 JP JP2022101881A patent/JP7617057B2/ja active Active
- 2022-10-19 US US17/969,105 patent/US20230287037A1/en not_active Abandoned
-
2023
- 2023-06-26 AU AU2023204015A patent/AU2023204015B2/en active Active
-
2025
- 2025-01-06 JP JP2025001804A patent/JP2025061026A/ja active Pending
- 2025-12-09 AU AU2025279604A patent/AU2025279604A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2738526T3 (es) | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos | |
| AU2025203873A1 (en) | Neuroactive steroids, compositions, and uses thereof | |
| WO2013188792A2 (en) | Neuroactive steroids, compositions, and uses thereof | |
| HK40018206A (en) | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof | |
| HK1201274B (en) | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof | |
| HK40120913A (zh) | 3，3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 | |
| HK40001824A (en) | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof | |
| HK40001824B (zh) | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |